news
Researchers have created a new view of how B cells recognise threats such as viruses
The researchers say their new discovery could be used to design better vaccines and to gain a deeper insight into autoimmune diseases and allergies.
List view / Grid view
Vaccine
news
Unlocking the secrets of Strep A virulence
Australian researchers have uncovered why some forms of Streptococcus A (Strep A) are associated with severe invasive infection.
news
Researchers discover small molecules that bind to SARS-CoV-2 spike proteins
The resulting compounds, which can bind to spike proteins from the original coronavirus, could serve as a starting point for developing broad-spectrum treatments for COVID-19.
article
Transformational vaccines that address global health challenges
Drug Target Review’s Izzy Wood spoke to Joseph Hernandez, CEO of Blue Water Vaccines, about developing transformational vaccines to address significant health challenges globally.
news
Mathematical model predicts long-term effectiveness of COVID-19 vaccine
US scientists have designed a mathematical model that can predict COVID-19 vaccines’ effectiveness over the long term in healthy individuals and those who have cancer or suppressed immune responses.
news
Novel cancer vaccine simultaneously kills and prevents brain cancer
US researchers develop a dual-action cell therapy engineered to eliminate established tumours and train the immune system to eradicate primary tumour and prevent cancer’s recurrence.
article
Latest developments in COVID-19 research
As COVID-19 continues to evolve, researchers are still on the lookout for new ways to protect against the virus. Drug Target Review brings you some of the most recent pre-clinical developments.
article
Progress towards an RSV vaccine
Despite decades without vaccine development in the respiratory syncytia virus (RSV) space, researchers are now homing in on a potential strategy to protect individuals from this disease. Here, Drug Target Review’s Ria Kakkad spoke with Dr Christy Comeaux, Medical Lead (RSV), Janssen, about the challenges associated with RSV vaccine development and her most promising…
article
Drug Target Review’s top content picks from 2022
In this article, Drug Target Review’s Izzy Wood and Ria Kakkad share some of the most ground-breaking moments from drug discovery this year.
news
New ALSV virus discovered in Swiss ticks
Researchers have detected Alongshan virus (ALSV) for the first time in Switzerland in ticks.
article
Silencing the messenger in elevated lipoprotein(a)
Elevated lipoprotein(a), or Lp(a), is a major risk factor for cardiovascular disease that affects one in five people worldwide, but currently lacks approved therapies. Here, Dr Giles Campion, EVP, Head of R&D and Chief Medical Officer of Silence Therapeutics, describes the company’s approach to developing an investigational siRNA therapy designed…
news
Where should the priority be for monkeypox vaccine allocations?
Canadian researchers underwent a modelling study to explore optimal allocation of vaccines against monkeypox virus (MPXV), that prioritises vaccines to larger networks with more initial infections and greater potential for spread is best.
article
Drug Target Review – Issue 4 2022
A new Drug Target Review issue is now ready to download! This issue features articles which explore how artificial intelligence can enhance screening and ways to find new hits through simultaneous orthogonal screens. Also included are articles on CRISPR, immuno-oncology and RSV vaccines.
news
Experimental mRNA vaccine protects against all 20-subtype influenza viruses
US researchers have tested mRNA-based vaccine against influenza viruses, with promising results in animal models, that pave the way for clinical trials.
news
Biovac and IVI sign ground breaking deal for the manufacturing of OCV
Biovac signs deal with IVI to develop and manufacture oral cholera vaccine (OCV) for African and global markets.